| Record Information |
| Version |
3.5 |
| Creation Date |
2007-04-12 17:21:17 -0600 |
| Update Date |
2013-02-08 17:14:32 -0700 |
| HMDB ID |
HMDB06111 |
| Secondary Accession Numbers |
|
| Metabolite Identification |
| Common Name |
12-HETE |
| Description |
12-hydroxyeicosatetraenoic acid (12-HETE) is an eicosanoid, a 5-lipoxygenase metabolite of arachidonic acid. 5-Lipoxygenase (LO)-derived leukotrienes are involved in inflammatory glomerular injury. LO product 12-HETE is associated with pathogenesis of hypertension, and may mediate angiotensin II and TGFbeta induced mesengial cell abnormality in diabetic nephropathy. 12-HETE is markedly elevated in the psoriatic lesions. 12-HETE is a vasoconstrictor eicosanoid that contribute to high blood pressure in (renovascular) hypertension and pregnancy-induced hypertension. A significant percentage of patients suffering from a selective increase in plasma LDL cholesterol (type IIa hyperlipoproteinaemia) exhibits increased platelet reactivity. This includes enhanced platelet responsiveness against a variety of platelet-stimulating agents ex vivo and enhanced arachidonic acid metabolism associated with increased generation of arachidonic acid metabolites such as 12-HETE, and secretion of platelet-storage products. (PMID: 7562532 , 12480795 , 17361113 , 8498970 ,1333255 , 2119633 ). 12-HETE is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-s-HETE analog has been reported to augment tumour cell metastatic potential through activation of protein kinase c. 12-HETE can be formed either in the 12-S or 12-R configuration. It has a diversity of biological actions and is generated by a number of tissues including the renal glomerulus and the vasculature. 12-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. 12-HETE is a neuromodulator that is synthesized during ischemia. Its neuronal effects include attenuation of calcium influx and glutamate release as well as inhibition of AMPA receptor (AMPA-R) activation. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (E,Z,Z,Z)-12-hydroxy-5,8,10,14-Eicosatetraenoate
- (E,Z,Z,Z)-12-hydroxy-5,8,10,14-Eicosatetraenoic acid
- 12-HETE
- 12-Hydroxy-5,8,10,14-eicosatetraenoate
- 12-Hydroxy-5,8,10,14-eicosatetraenoic acid
- 12-Hydroxy-5E,8Z,10Z,14Z-eicosatetraenoate
- 12-Hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid
- 12-Hydroxyeicosatetraenoate
- 12-Hydroxyeicosatetraenoic acid
|
| Chemical Formula |
C20H32O3 |
| Average Molecular Weight |
320.4663 |
| Monoisotopic Molecular Weight |
320.23514489 |
| IUPAC Name |
(5E,8Z,10Z,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid |
| Traditional IUPAC Name |
12-hete |
| CAS Registry Number |
71030-37-0 |
| SMILES |
CCCCC\C=C/CC(O)\C=C/C=C\C\C=C\CCCC(O)=O |
| InChI Identifier |
InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7+,11-8-,13-10-,17-14- |
| InChI Key |
ZNHVWPKMFKADKW-FYMOKONMSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Lipids |
| Class |
Eicosanoids |
| Sub Class |
Hydroxyeicosatetraenoic Acids |
| Other Descriptors |
- Aliphatic Acyclic Compounds
- Hydroxy Fatty Acids
- Organic Compounds
- Straight Chain Fatty Acids
- Unsaturated Fatty Acids
- hydroxy monocarboxylic acid(ChEBI)
|
| Substituents |
- Acyclic Alkene
- Allyl Alcohol
- Carboxylic Acid
- Secondary Alcohol
|
| Direct Parent |
Hydroxyeicosatetraenoic Acids |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Cell signaling
- Fuel and energy storage
- Fuel or energy source
- Membrane integrity/stability
|
| Application |
- Nutrients
- Stabilizers
- Surfactants and Emulsifiers
|
| Cellular locations |
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
Not Available
|
| Biological Properties |
| Cellular Locations |
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Urine
|
| Tissue Location |
Not Available
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.00422 +/- 0.000292 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
0.35 +/- 0.25 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
6.42 +/- 0.74 uM |
Adult (>18 years old) |
Not Specified |
Normal |
HM Replicate Plasma (n=3)
|
| Blood |
Detected and Quantified |
|
0.0526 +/- 0.0944 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
3.95 +/- 3.3 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Pennington Plasma (n=70)
|
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.0 - 0.001 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.00091 +/- 0.00031 uM |
Adult (>18 years old) |
Both |
Normal |
Measured via MS/MS techniques from 4 pooled CSF...
|
|
| Abnormal Concentrations |
|
| Cerebrospinal Fluid (CSF) |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Cerebral Vasospasm |
Symptomatic cerebral vasospasm
Concentration...
|
| Urine |
Detected and Quantified |
|
0.0000001 (0.00-0.0000001) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Zellweger syndrome |
Not Available |
| Urine |
Detected and Quantified |
|
0.0000054 (0.0000035-0.0000074) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Zellweger syndrome |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Cerebral vasospasm |
- Poloyac SM, Reynolds RB, Yonas H, Kerr ME: Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods. 2005 Jun 15;144(2):257-63. Epub 2004 Dec 30.
Pubmed: 15910986
|
| Peroxisomal biogenesis defect |
- http://www.metagene.de/program/d.prg?mp=ZELLWEGER%20SYNDROME
|
|
| Associated OMIM IDs |
- 214100
(Peroxisomal biogenesis defect)
|
| External Links |
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB001435 |
| KNApSAcK ID |
C00000424  |
| Chemspider ID |
4472408  |
| KEGG Compound ID |
Not Available |
| BioCyc ID |
Not Available |
| BiGG ID |
Not Available |
| Wikipedia Link |
Not Available |
| NuGOwiki Link |
HMDB06111  |
| Metagene Link |
HMDB06111  |
| METLIN ID |
Not Available |
| PubChem Compound |
5312983  |
| PDB ID |
Not Available |
| ChEBI ID |
Not Available |
| References |
| Synthesis Reference |
Not Available |
| Material Safety Data Sheet (MSDS) |
Not Available
|
| General References |
Not Available
|